Mindful DNA™, Genetic Testing for Personalized Wellness, Forms Wellness Advisory Board of Medical and Research Leaders
KING OF PRUSSIA, Pa, July 16, 2018 /PRNewswire/ -- Genomind®, the developer of the Mindful DNA genetic test, is proud to announce the formation of a new Wellness Advisory Board. The distinguished board members play important roles in the continued development of Mindful DNA and will advise the company on the uses of genetic markers to guide lifestyle, diet, and nutritional decisions to improve overall health and wellbeing.
The test provides evidence-based, personalized, actionable information that helps patients adjust their lifestyle, diet, habits and activities to improve their overall quality of life.
Board member Sara Gottfried, M.D., is the New York Times bestselling author of "The Hormone Cure," "The Hormone Reset Diet" and "Younger." She is the Founder and CEO of the Gottfried Institute based in Berkeley, California and is a board-certified OB/GYN. She graduated from Harvard Medical School and the Massachusetts Institute of Technology, and completed residency at the University of California at San Francisco. Over the past two decades, Dr. Gottfried has seen more than 25,000 patients, and specializes in identifying the underlying cause of her patients' conditions to achieve true and lasting health transformations, not just symptom management.
"It's an honor to serve in this role because I am confident that Mindful DNA is a breakthrough in personalized wellness," says Dr. Gottfried. "The test analyzes variations in 32 key genes in six areas, or domains, of health. …These are exactly the areas patients are looking for guidance in terms of treatment and solutions."
These six domains are: Cognition & Mental Acuity, Cardiometabolic, Gastrointestinal (GI) & Immune, Stress & Emotional Wellbeing, Inflammation, and Sleep.
The other distinguished members of the Wellness Scientific Advisory Board are:
Susan Blum, M.D., M.P.H., is the Founder and Director of Blum Center for Health, the Co-Founder and Chief Medical Officer of Organic Pharmer Health Food Eatery, is a senior teaching faculty member at the Center for Mind-Body Medicine in Washington D.C., and is a Clinical Assistant Professor in the Department of Preventive Medicine at The Icahn School of Medicine at Mount Sinai. Following a functional medicine approach, Dr. Blum is focused on finding and treating the triggers that cause disease.
Kathie Madonna Swift, M.S., R.D.N., L.D.N., F.A.N.D., is the Founder of the Kathie Swift Integrative and Functional Nutrition Practice and the Co-Founder of the Integrative and Functional Nutrition Academy. Additionally, she is a nutritionist and the former Nutrition Director at Dr. Mark Hyman's UltraWellness Center, is the Senior Nutritionist and former Lead Nutritionist at the Kripalu Center for Yoga & Health, is a nutritionist and the former Nutrition Director at Canyon Ranch in the Berkshires, and is nutritional education director at the Center for Mind-Body Medicine in Washington D.C. Kathie has 30 plus years of expertise in "whole food as medicine" and is committed to a holistic and integrative approach to nutrition.
In addition, two current members of Genomind's Scientific Advisory Board will serve in a similar capacity on the Wellness Advisory Board.
Maurizio Fava, M.D., is Director, Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, Executive Vice Chair of the Department of Psychiatry, Founder and Executive Director of the MGH Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry, and Associate Dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School. He also founded and directed (1990-2014) the MGH Depression Clinical and Research Program (DCRP) which is one of the most highly regarded depression programs in the country. A model for other academic programs, the DCRP links clinical and research work, bi-directionally.
Rudolph E. Tanzi, Ph.D., is the Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital, and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr. Tanzi served on the team that was the first to find a disease gene (Huntington's disease) using human genetic markers, helping to launch the field of neurogenetics. Through his research, he also discovered the Wilson's disease gene and several other neurological disease genes. Dr. Tanzi then went on to co-discover all three early-onset familial Alzheimer's disease genes and has identified several other AD genes during his role as leader of the Alzheimer's Genome Project, a research project of the Cure Alzheimer's Fund.
Genomind, which has conducted over 150,000 genetic tests for patients around the world, developed Mindful DNA after a comprehensive and through systematic literature review of hundreds of studies that were then weighted and scored for evidence of benefits on health outcomes. Mindful DNA can identify genetic variations that can help providers deliver deeply personalized, integrative care to every patient. It can also empower patients to see their health holistically and take action to improve it. Testing is simple and quick: Sample collection is done by cheek swab, and results are returned to the ordering clinician in 10 days or less. Healthcare providers who are interested in using Mindful DNA with their patients can order test kits at genomind.com/orderMindfulDNA. Patients who are interested in speaking with their healthcare providers about receiving this test can learn more at genomind.com/MindfulDNA/patients and find a downloadable, printable resource to bring to their clinician to aid in their discussion.
About Mindful DNA
Mindful DNA is a genetic test used by clinicians that helps guide lifestyle, diet and nutritional supplement decisions to improve the overall health and wellbeing of patients. It was created based on Genomind's expertise in brain health and belief in the importance of the mind-body connection. The results report provides personalized, actionable information that helps patients adjust their lifestyle, habits and activities in order to improve their quality of life. The test analyzes 32 genes in six key areas, or domains, of health: Cognition & Mental Acuity, Cardiometabolic, GI & Immune, Stress & Emotional Wellbeing, Inflammation, and Sleep. For each at-risk gene result, the test report specifies holistic steps patients can take in collaboration with their healthcare provider to achieve better health. Learn more at www.genomind.com.
About Genomind
Genomind® is a unique personalized medicine platform that brings innovation to healthcare around the world. Genomind, comprised of pioneering scientists and thought leaders in brain health and genetics, delivers actionable insights to clinicians, healthcare partners and individuals in order to improve the quality of human life. Learn more at www.genomind.com.
MEDIA CONTACTS:
Adam Shapiro
ASPR
202-427-3603
[email protected]
Amy Pressman
Genomind
267-989-3426
[email protected]
SOURCE Genomind
Share this article